好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

CD163+ Microglia-Macrophages in the Multiple Sclerosis Spinal Cord Associate with Aberrant Iron Distribution and Indicate Blood Brain Barrier Dysfunction
Multiple Sclerosis
S33 - Multiple Sclerosis: Biomarkers in MS (4:54 PM-5:06 PM)
008

A subset of MS brain lesions contain a rim of iron-laden macrophages, detectable with MRI, which correlate with disability. CD163, a scavenger receptor for haemoglobin-haptoglobin complexes, is upregulated in MS brain lesions, but its expression in the clinically relevant spinal cord is unknown.

To assess expression of CD163+ in the MS spinal cord and relate this to iron deposition.

Cervical and lumbar spinal cord sections from 44 progressive MS and 5 control cases were immunostained for CD163, microglia-macrophages (Iba1,CD68), lymphocytes (CD3,CD8,CD20) and myelin (PLP), with lesions staged using CD68. CD163+ cell density was quantified in fields-of-view (FOV) centred on vessels, and 100μm-wide surrounding regions, in non-lesional white matter (NLWM), and in meninges. Iron was detected histochemically using DAB-enhanced Turnbull-Blue staining and iron deposition in cellular compartments (axons, macrophages, astrocytes) was assessed semi-quantitatively. A subset of 20 cases were stained for haptoglobin, which was quantified using an automated pixel-count algorithm.

In controls, CD163+ was confined to vessels and meninges. In MS, CD163+ was seen throughout active lesions, at the rim of mixed active/inactive lesions, and in the NLWM. Iron+ axons were preferentially located in the lateral columns, where their presence related to parenchymal CD163 (ρ=.351,p=0.012). This was maintained correcting for total Iba-1 and CD68 densities. On evaluating MS cases with and without iron+ axons, CD163+ counts were higher in iron+ compared to iron- cases (p=0.004) or control (p=0.038). Meningeal CD163 density did not associate with iron scores, but rather with meningeal lymphocyte inflammation. Haptoglobin coverage was higher in high-CD163+ MS vs low-CD163+ MS cases (p=0.0334)

CD163+ microglia/macrophages are elevated in MS cases exhibiting abnormal iron distribution. CD163+ density relates to haptoglobin deposition in the spinal cord. Together these findings suggest that leakage of blood products across damaged vessels may be an important source of pathological iron in the MS spinal cord.

Authors/Disclosures
Andrew Lockhart, MB, BAO, BCh, MSc (University of Oxford)
PRESENTER
The institution of Dr. Lockhart has received research support from Oxford-Quinnipiac Partnership. The institution of Dr. Lockhart has received research support from European Charcot Foundation.
Xinran Zhang Miss Zhang has nothing to disclose.
Marco Pisa, MD (Nuffield Department of Clinical Neurosciences, University of Oxford) Dr. Pisa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Aimee Avery (University of Oxford) The institution of Aimee Avery has received research support from UK MS Society. The institution of Aimee Avery has received research support from US Deparment of Defense.
Jonathan Pansieri, PhD (University of Oxford) The institution of Dr. Pansieri has received research support from UK-MS society. The institution of Dr. Pansieri has received research support from Department of Defense US. Dr. Pansieri has received personal compensation in the range of $0-$499 for serving as a member of the Grant review Panel with French National Agency. Dr. Pansieri has received personal compensation in the range of $500-$4,999 for serving as a recipee of Travel Grant with Brain.
Hal Drakesmith, PhD Prof. Drakesmith has nothing to disclose.
Gabriele C. De Luca, MD, DPhil, FAAN (University of Oxford) Dr. De Luca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurology Academy. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. De Luca has received research support from NIHR, BRC (Oxford). The institution of Dr. De Luca has received research support from National Health and Medical Research (Australia). The institution of Dr. De Luca has received research support from UK MS Society. The institution of Dr. De Luca has received research support from Oxford-Quinnipiac Partnership. The institution of Dr. De Luca has received research support from US Department of Defense. The institution of Dr. De Luca has received research support from Wellcome ISSF (Oxford). The institution of Dr. De Luca has received research support from Bristol Myers Squibb. The institution of Dr. De Luca has received research support from University of Oxford (John Fell Fund). The institution of Dr. De Luca has received research support from National Health and Medical Research (Australia). Dr. De Luca has a non-compensated relationship as a Editorial board member with MS Journal that is relevant to AAN interests or activities. Dr. De Luca has a non-compensated relationship as a Vice-Chair of Grant Review Panel with UK MS Society that is relevant to AAN interests or activities. Dr. De Luca has a non-compensated relationship as a Steering Group member with MS Academy that is relevant to AAN interests or activities. Dr. De Luca has a non-compensated relationship as a Board of Directors with SEQUINS that is relevant to AAN interests or activities.